FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Mecasermin [rDNA origin] (Increlex) Injection
Status: Resolved
»Duration of Shortage: 04/26/2012 - 11/08/2017
»Therapeutic Categories: Endocrinology/Metabolism; Pediatric

Ipsen Biopharmaceuticals Inc. (Revised 11/08/2017)

Company Contact Information:
866-435-5677

Presentation
  • INCRELEX (mecasermin [rDNA origin] injection), 10 mg/mL (NDC-15054-1040-5)
Note:
  • Available

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English